Skip to main content
logo
BioXcel Therapeutics, Inc. (BTAIQ)
OTCMKTS · Delayed Price · Currency is USD
0.0130
-0.000485 (-3.60%)
At close: Oct 30, 2026

BioXcel Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.740.642.271.380.38-
Revenue Growth
-14.52%-71.67%64.20%268.00%--
Gross Profit
0.390.480.120.120.36-
Operating Income
-44.73-50.27-64.8-167.62-159.65-106.94
Net Income
-70.86-69.9-59.6-179.05-165.76-106.93
Earnings Per Share
-3.15-5.73-23.51-98.33-94.67-64.87
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
12.8428.4229.8565.22193.73232.97
Total Debt
104.45109.66102.57101.0493.841.11
Net Cash (Debt)
-91.61-81.24-72.72-35.8299.89231.86
Net Cash Growth
-----56.92%9.51%
Net Cash Per Share
-4.07-6.65-28.69-19.6757.05140.67

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-50.9-57.62-72.03-155.01-135.34-82.15
Capital Expenditures
----0.02-0.14-0.45
Free Cash Flow
-50.9-57.62-72.03-155.03-135.48-82.6
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
53.10%74.45%5.43%8.70%94.67%-
Operating Margin
-6028.57%-7829.75%-2859.84%-12146.30%-42572.00%-
Pretax Margin
-9549.87%-10887.38%-2630.14%-12974.86%-44201.87%-
Profit Margin
-9549.86%-10887.38%-2630.14%-12974.85%-44201.87%-
FCF Margin
-6860.38%-8974.30%-3178.60%-11233.77%-36128.00%-

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.5554.508.1962.581605.17-